Biotech Values

[DewDiligence]

LPTN—Due to the stock’s continuing to sell well below net cash per share, in due course LPTN will likely be the target of a reverse merger with a private company. In such a transaction, the private company will own the large majority of the merged company, and LPTN’s contribution will consist almost entirely of cash and the public listing.